Cargando…
Octagam(®) for chronic inflammatory demyelinating polyneuropathy: results from three observational studies
AIM: To present data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving Octagam(®) 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Data on patients with CIDP treated with Octagam were analyzed to assess...
Autor principal: | Wietek, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190209/ https://www.ncbi.nlm.nih.gov/pubmed/29517417 http://dx.doi.org/10.2217/nmt-2018-0006 |
Ejemplares similares
-
Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
por: Belmokhtar, Chafké, et al.
Publicado: (2019) -
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
por: Chaudhary, Umair J., et al.
Publicado: (2020) -
Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018) -
Tolerability and safety of Octagam(®) (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
por: Frenzel, Wolfgang, et al.
Publicado: (2016) -
The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes – An Observational Study
por: Dunnigan, Samantha K., et al.
Publicado: (2014)